Jennison Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.3B | Buy |
|
|||||
|
2025
Q1 | $1.31B | Sell |
|
|||||
|
2024
Q4 | $1.72B | Sell |
|
|||||
|
2024
Q3 | $2.4B | Sell |
|
|||||
|
2024
Q2 | $3.03B | Buy |
|
|||||
|
2024
Q1 | $2.71B | Sell |
|
|||||
|
2023
Q4 | $2.33B | Sell |
|
|||||
|
2023
Q3 | $2.13B | Buy |
|
|||||
|
2023
Q2 | $1.89B | Sell |
|
|||||
|
2023
Q1 | $1.96B | Buy |
|
|||||
|
2022
Q4 | $1.55B | Buy |
|
|||||
|
2022
Q3 | $1.09B | Buy |
|
|||||
|
2022
Q2 | $1.17B | Buy |
|
|||||
|
2022
Q1 | $614M | Buy |
|
|||||
|
2021
Q4 | $74.5M | Buy |
|
|||||
|
2021
Q3 | $46.9M | Buy |
|
|||||
|
2021
Q2 | $40.9M | Sell |
|
|||||
|
2021
Q1 | $32.9M | Sell |
|
|||||
|
2020
Q4 | $46.6M | Sell |
|
|||||
|
2020
Q3 | $70M | Buy |
|
|||||
|
2020
Q2 | $65.1M | Sell |
|
|||||
|
2020
Q1 | $69.4M | Buy |
|
|||||
|
2019
Q4 | $65.5M | Buy |
|
|||||
|
2019
Q3 | $58M | Sell |
|
|||||
|
2019
Q2 | $62.8M | Buy |
|
|||||
|
2019
Q1 | $34M | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $267M | Sell |
|
|||||
|
2016
Q2 | $936M | Buy |
|
|||||
|
2016
Q1 | $810M | Sell |
|
|||||
|
2015
Q4 | $869M | Sell |
|
|||||
|
2015
Q3 | $986M | Sell |
|
|||||
|
2015
Q2 | $1.08B | Sell |
|
|||||
|
2015
Q1 | $1.25B | Sell |
|
|||||
|
2014
Q4 | $1.02B | Sell |
|
|||||
|
2014
Q3 | $1.34B | Buy |
|
|||||
|
2014
Q2 | $1.24B | Buy |
|
|||||
|
2014
Q1 | $1.21B | Buy |
|
|||||
|
2013
Q4 | $964M | Sell |
|
|||||
|
2013
Q3 | $957M | Sell |
|
|||||
|
2013
Q2 | $1.04B | Buy |
|